

Douwe F Samplonius

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2688535/publications.pdf>

Version: 2024-02-01

16
papers

347
citations

933447

10
h-index

940533

16
g-index

16
all docs

16
docs citations

16
times ranked

695
citing authors

#	ARTICLE	IF	CITATIONS
1	CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCR β^+ CD8 α^+ T cells that can be targeted for cancer immunotherapy. <i>Oncotarget</i> , 2016, 7, 75130-75144.	1.8	64
2	CD20-selective inhibition of CD47-SIRP α signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab. <i>Oncolmunology</i> , 2018, 7, e1386361.	4.6	58
3	A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint. <i>Oncolmunology</i> , 2018, 7, e1466016.	4.6	42
4	Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction. <i>Oncolmunology</i> , 2016, 5, e1202390.	4.6	35
5	Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRP α immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation. <i>Oncolmunology</i> , 2020, 9, 1824323.	4.6	25
6	Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade. <i>Journal of Investigative Dermatology</i> , 2019, 139, 2343-2351.e3.	0.7	20
7	Melanoma-Directed Activation of Apoptosis Using a Bispecific Antibody Directed at MCSP and TRAIL Receptor-2/Death Receptor-5. <i>Journal of Investigative Dermatology</i> , 2016, 136, 541-544.	0.7	18
8	CD20 ⁺ T cells have a predominantly Tc1 effector memory phenotype and are expanded in the ascites of patients with ovarian cancer. <i>Oncolmunology</i> , 2015, 4, e999536.	4.6	17
9	A CD47 blocking TRAIL fusion protein with dual prophagocytic and proapoptotic anticancer activity. <i>British Journal of Haematology</i> , 2014, 164, 304-307.	2.5	15
10	Modular Medical Imaging Agents Based on Azide-Alkyne Huisgen Cycloadditions: Synthesis and Preclinical Evaluation of ¹⁸ F-Labeled PSMA Tracers for Prostate Cancer Imaging. <i>Chemistry - A European Journal</i> , 2020, 26, 10871-10881.	3.3	13
11	Bispecific antibody CD73xEpCAM selectively inhibits the adenosine-mediated immunosuppressive activity of carcinoma-derived extracellular vesicles. <i>Cancer Letters</i> , 2021, 521, 109-118.	7.2	12
12	Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition. <i>Oncogene</i> , 2019, 38, 1477-1488.	5.9	11
13	Synthesis and Evaluation of 18F-Enzalutamide, a New Radioligand for PET Imaging of Androgen Receptors: A Comparison with ¹⁶ I ² -18F-Fluoro-5 α -Dihydrotestosterone. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1140-1145.	5.0	7
14	A versatile pretargeting approach for tumour-selective delivery and activation of TNF superfamily members. <i>Scientific Reports</i> , 2017, 7, 13301.	3.3	6
15	Cancer cells under immune attack acquire CD47-mediated adaptive immune resistance independent of the myeloid CD47-SIRP α axis. <i>Oncolmunology</i> , 2021, 10, 2005344.	4.6	3
16	A proof-of-concept study on the use of a fluorescein-based 18F-tracer for pretargeted PET. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2022, 7, 3.	3.9	1